“We are very excited to continue to strengthen the RxSight Board of Directors with the additions of Dr. Fountain and Ms. Maniar. Their diverse healthcare leadership experience will support the strategic advancement of the company through its next chapter of growth,” J. Andy Corley, Chair of the Board of Directors, said in a company news release.
“We look forward to their respective contributions as the RxSight Light Adjustable Lens system provides more doctors and patients the ability to customize and optimize their vision following cataract surgery.”
Dr. Fountain is an ophthalmologist who served as President of the American Academy of Ophthalmology in 2021 and was elected to the American Board of Ophthalmology's board of directors in January 2022.
Dr. Fountain was chair for Alumni Fund Giving at Harvard Medical School from January 2016 to June 2019 and served as President of the American Society of Ophthalmic Plastic and Reconstructive Surgery in 2018.
She was a member of the board of directors of Ophthalmic Mutual Insurance Company (OMIC), the largest professional liability insurance for ophthalmologists in the United States by market share.
At the end of her term, Dr. Fountain was elected OMIC’s first woman chair of the Board and chair of the Audit Committee, serving January 2014 to December 2015. She was President of the Illinois Society of Eye Physicians and Surgeons from January 2002 to December 2005.
Dr. Fountain received her B.A. in Human Biology from Stanford University, her M.D. from Harvard Medical School, and completed her residency in ophthalmology at Johns Hopkins Hospital’s Wilmer Eye Institute.
Ms. Maniar is the Global Leader, Healthcare & Life Sciences Solutions, Google Cloud - BioPharma at Google, where she is in charge of the company's industry product strategy and go-to-market approach.
Prior to joining Google, she worked at Genentech as an executive from November 2013 to June 2018, where she oversaw market expansion strategies for technology accelerators for treatments and diagnostics.
For more than a year previously, Ms. Maniar formerly worked at Summa Health as the Director of the Center for Minimally Invasive Therapeutics. Earlier in her career, she worked in research at the Cleveland Clinic and the Austen BioInnovation Institute in Akron, where she primarily focused on medical devices and minimally invasive therapies.
She currently serves on the board of directors of SeaSpine Holdings Corporation and is a member of the Compensation Committee. Ms. Maniar holds a B.A. in Economics from the University of California, San Diego.